Ranbaxy Laboratories signs agreement with Medy-Tox for Neuronox
RBXLF | Quote | Chart | News | PowerRating -- Ranbaxy Laboratories Limited, an India-based research-based pharmaceutical company, has entered into an in-licensing agreement with Medy-Tox, Inc., a Korea-based biotechnology company, for Neuronox, a cosmetic product.
Deal Type Partnership
Sub-Category Licensing Agreement
Deal Status Announced: 2009-09-17
Deal Participants
Partner 1 (Company) Medy-Tox, Inc.
Partner 2 (Company) Ranbaxy Laboratories Limited
Deal Rationale
The licensing agreement would enable Ranbaxy Laboratories to strengthen its presence in the dermatological segment.
For full details on (RBXLF) RBXLF. (RBXLF) has Short Term PowerRatings at TradingMarkets. Details on (RBXLF) Short Term PowerRatings is available at This Link.
- Syntropharma signs marketing agreement with Ranbaxy Pharmaceuticals for generic transdermal product - 02/02/10
- Ranbaxy launches anti-fungal chemical in India - 01/11/10
- Ranbaxy in talks to acquire Bangalore vaccine co for Rs 50-cr - 01/08/10
- Ranbaxy Laboratories signs license agreement with Summit Pharmaceuticals for Lulifin (Luliconazole) - 01/07/10
- Ranbaxy to transfer stake in Chinese operations to Chembio Pharmacy - 01/07/10
- More News >>


